DOCKET NO: ISIS0055-100 (RTS-0236) **PATENT**

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please amend claim 1 and cancel claims 20-24, 26-28, 30, and 32-40 as indicated below.

1. (currently amended) A modified compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding EIF2C1 (SEQ ID NO:3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding EIF2C1 and inhibits the expression of EIF2C1 by at least 42%.

2. (original) The compound of claim 1 which is an antisense oligonucleotide.

3. (canceled).

4. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. (original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. (original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. (original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. (original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (original) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding EIF2C1.

12. (original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (original) The composition of claim 12 further comprising a colloidal dispersion system.

14. (original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. (previously presented) A method of inhibiting the expression of EIF2C1 in cells or tissues comprising contacting cells or tissues *in vitro* with the compound of claim 1 so that expression of EIF2C1 is inhibited.

16-28. (canceled).

29. (previously presented) The compound of claim 1 wherein said compound inhibits EIF2C1 expression by at least 60%.

30. (canceled).

31. (previously presented) The compound of claim 29 wherein said compound inhibits EIF2C1 expression by at least 80%.

32-40. (cancelled).